osimertinib
astrazeneca
['lung', 'adaura', 'nsclc', 'sclc', 'osimertinib', 'astrazeneca', 'aura ,(-laura)']
adjuvant osimertinib reduced risk for death by 51% in egfr-mutant lung cancer, per updated adaura trial data presented at #asco23 plenary. #nsclc 
The content you need, when you need it.